India approves AstraZeneca and local Covid vaccines, rollout in weeks

Published January 3, 2021
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters

India’s drugs regulator on Sunday gave final approval for the emergency use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.

The world’s second most populous country is now expected to start a massive immunisation programme within weeks, with the AstraZeneca/Oxford shot taking the lead and Bharat Biotech’s Covaxin administered under stricter conditions given that no efficacy data has been released for it.

The overall efficacy of the AstraZeneca/Oxford vaccine was 70.42 per cent, while Bharat Biotech’s Covaxin was “safe and provides a robust immune response”, said Drugs Controller General of India VG Somani.

The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded Covishield, while Bharat Biotech has teamed up with the government run Indian Council of Medical Research.

“Vaccines of Serum [Institute of India] and Bharat Biotech are being approved for restricted use in emergency situations,” Somani read out from a written statement at a press conference. Somani did not take questions.

Both vaccines will be administered in two doses and stored at two to eight degrees Celsius, he said. Sources told Reuters on Saturday the doses would have to be given four weeks apart.

Somani explained that the Bharat Biotech vaccine had been approved “in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains”.

Prime Minister Narendra Modi welcomed the approvals.

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!” he said on Twitter, calling it a sign of a “self-reliant” country.

SII, the world’s biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even without a formal supply deal with the government.

“All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off,” CEO Adar Poonawalla said on Twitter. “Covishield, India’s first Covid-19 vaccine, is approved, safe, effective and ready to roll out in the coming weeks.”

Opinion

Editorial

Budget and politics
Updated 14 Jun, 2024

Budget and politics

PML-N, scared of taking bold steps lest it loses whatever little public support it has, has left its traditional support — traders — virtually untouched.
New talks?
14 Jun, 2024

New talks?

WILL this prove another false start, or may we expect a more sincere effort this time? Reference is made to the...
A non-starter
14 Jun, 2024

A non-starter

WHILE the UN Security Council had earlier this week adopted a US-backed resolution calling for a ceasefire in Gaza...
Budget for stabilisation
Updated 13 Jun, 2024

Budget for stabilisation

The proposed steps lack any “disruptive policy changes", especially to "right-size" the govt, and doubts remain on authorities' ability to enforce new measures.
State of the economy
13 Jun, 2024

State of the economy

THE current fiscal year is but another year lost. Going by the new Pakistan Economic Survey, which maps the state of...
Unyielding onslaught
Updated 13 Jun, 2024

Unyielding onslaught

SEVEN soldiers paid the ultimate price in Lakki Marwat on Sunday when their vehicle was blown up in an IED attack,...